| NCT ID | NCT06541145 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Duke University |
| Condition | Bacterial Colonization |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2024-08-21 |
| Primary Completion | 2026-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2024-08-21 with a primary completion date of 2026-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to measure bacterial burden, specifically Staph aureus, and how it spreads between mothers and their infants. Researchers will evaluate if the amount of bacteria on their skin remains the same after mothers use a skin antisepsis treatment prior to delivering their infants. The investigators also aim to assess participant interest in and compliance with skin antisepsis treatments. The hypothesis is that increased maternal interest will align with increased treatment compliance.
Eligibility Criteria
Inclusion Criteria: * Participants must be enrolled in longitudinal study Project HOPE1000. Exclusion Criteria: * Participants not enrolled in Project HOPE1000 will be excluded.
Contact & Investigator
Ibukunoluwa Kalu, MD
PRINCIPAL INVESTIGATOR
Duke University
Frequently Asked Questions
Who can join the NCT06541145 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Bacterial Colonization. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06541145 currently recruiting?
Yes, NCT06541145 is actively recruiting participants. Contact the research team at ica5@duke.edu for enrollment information.
Where is the NCT06541145 trial being conducted?
This trial is being conducted at Durham, United States.
Who is sponsoring the NCT06541145 clinical trial?
NCT06541145 is sponsored by Duke University. The principal investigator is Ibukunoluwa Kalu, MD at Duke University. The trial plans to enroll 20 participants.